Argumentative Indians are at it again! After sparring over the poverty line and the actual number of poor, India's renowned economists have fired up a fresh debate over the extent of malnutrition. In the earlier debate, the Planning Commission ‘reduced' poverty on paper disregarding NSSO and official committees, including the NCEUS, which determined that 77% Indians survived on less than Rs 20 a day. Columbia university economist Arvind panagariya has...

-The Times of India NEW DELHI: The expert panel to decide the new yardstick for backward states, meant to benefit states such as Bihar, kicked off discussion on Tuesday with committee members looking at possible parameters. Sources present in the meeting said some historical and social indicators were discussed but talks were exploratory. "It was a broad discussion. It will take a few more sittings to come to any conclusion," said Asian...

-Live Mint Rural development minister Jairam Ramesh said the committee's recommendations will be accepted New Delhi: A government committee has recommended issuing below-poverty-line (BPL) cards to all 4 million households in 22 backward districts that are affected by the Maoist insurgency. The committee, set up by the rural development ministry, also recommended the inclusion in another 34 such districts of households that are headed by a scheduled caste or scheduled tribe member,...

-The Telegraph The sudden arrest of Amway India's top brass on Monday has focused the spotlight on the crumbling fault lines and the grey areas in the demarcation between some of the world's best-known direct selling companies and the dodgy Ponzi schemes that promise huge returns to gullible investors and have lately grabbed all the sensational headlines in Bengal. William S. Pinckney, managing director of Amway India, and two directors of the...

-The Business Standard USFDA's zero tolerance policy requires our drug firms to reorient not just processes but organisational cultures to serve that market credibly The following two quotes from the United States Food and Drug Administration (FDA) news releases may help put the Ranbaxy controversy in perspective. The first sums up what it is that drives the FDA and the second is typical of the challenge the pharmaceutical industry faces. (1) "The consent...